Targeting Mnks for cancer therapy (scientific article published on February 2012)

Therapeutic inhibition of MAP kinase interacting kinase blocks eukaryotic initiation factor 4E phosphorylation and suppresses outgrowth of experimental lung metastases

Q83201881

Negative regulation of protein translation by mitogen-activated protein kinase-interacting kinases 1 and 2

Q24291466

The mTOR/PI3K and MAPK pathways converge on eIF4B to control its phosphorylation and activity

Q24293101

Identification of novel phosphorylation sites required for activation of MAPKAP kinase-2

Q24312661

Rak functions as a tumor suppressor by regulating PTEN protein stability and function

Q24312999

MNK1 and MNK2 regulation in HER2-overexpressing breast cancer lines

Q24320171

MNK1, a new MAP kinase-activated protein kinase, isolated by a novel expression screening method for identifying protein kinase substrates

Q24322852

Distinct signaling events downstream of mTOR cooperate to mediate the effects of amino acids and insulin on initiation factor 4E-binding proteins

Q24519078

Mitogen-activated protein kinases activate the serine/threonine kinases Mnk1 and Mnk2

Q24532154

Human eukaryotic translation initiation factor 4G (eIF4G) recruits mnk1 to phosphorylate eIF4E

Q24533512

The mitogen-activated protein kinase signal-integrating kinase Mnk2 is a eukaryotic initiation factor 4E kinase with high levels of basal activity in mammalian cells

Q24551026

The selectivity of protein kinase inhibitors: a further update

Q24654622

Targeting the mTOR signaling network for cancer therapy

Q24658334

The N and C termini of the splice variants of the human mitogen-activated protein kinase-interacting kinase Mnk2 determine activity and localization

Q24679177

Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site

Q27638349

Discovery and characterization of 2-anilino-4- (thiazol-5-yl)pyrimidine transcriptional CDK inhibitors as anticancer agents

Q27665462

eIF4 initiation factors: effectors of mRNA recruitment to ribosomes and regulators of translation

Q27860920

Upstream and downstream of mTOR

Q28277365

Identification and molecular characterization of Mnk1b, a splice variant of human MAP kinase-interacting kinase Mnk1

Q28280562

The serine-threonine kinase MNK1 is post-translationally stabilized by PML-RARalpha and regulates differentiation of hematopoietic cells

Q28290732

The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins

Q28507365

Loss of MNK function sensitizes fibroblasts to serum-withdrawal induced apoptosis

Q28512029

Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity

Q29614241

ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions

Q29615216

Rational design of inhibitors that bind to inactive kinase conformations

Q29617558

Molecular mechanisms of translation initiation in eukaryotes

Q29619902

MNK kinases regulate multiple TLR pathways and innate proinflammatory cytokines in macrophages

Q30445072

CART classification of human 5' UTR sequences

Q30961644

Expression of translation initiation factors elF-4E and elF-2alpha and a potential physiologic role of continuous protein synthesis in human platelets

Q32007572

Phosphorylated eukaryotic translation initiation factor 4 (eIF4E) is elevated in human cancer tissues

Q33584507

Translational control: the cancer connection

Q33601620

eIF4E activity is regulated at multiple levels

Q33601634

eIF4E expression in tumors: its possible role in progression of malignancies

Q33601639

MNK1 and EIF4E are downstream effectors of MEKs in the regulation of the nuclear export of HDM2 mRNA.

Q40082913

Characterization of the activity of human MAP kinase-interacting kinase Mnk1b.

Q40115627

Structural bioinformatics-based design of selective, irreversible kinase inhibitors

Q40307105

Features in the N and C termini of the MAPK-interacting kinase Mnk1 mediate its nucleocytoplasmic shuttling

Q40638945

Phosphorylation of eukaryotic initiation factor 4E markedly reduces its affinity for capped mRNA.

Q40766564

Antisense RNA to eIF4E suppresses oncogenic properties of a head and neck squamous cell carcinoma cell line.

Q40874096

Reduction of translation initiation factor 4E decreases the malignancy of ras-transformed cloned rat embryo fibroblasts

Q41379829

Decreasing the level of translation initiation factor 4E with antisense RNA causes reversal of ras-mediated transformation and tumorigenesis of cloned rat embryo fibroblasts.

Q41514552

Cloning and characterization of KNR4, a yeast gene involved in (1,3)-beta-glucan synthesis

Q41812375

Expression of the eukaryotic translation initiation factors 4E and 2alpha in non-Hodgkin's lymphomas

Q41822752

The C-terminal domain of Mnk1a plays a dual role in tightly regulating its activity

Q42457882

Mitogen-activated protein kinases interacting kinases are autoinhibited by a reprogrammed activation segment

Q42763653

Upregulation of protein synthesis initiation factor eIF-4E is an early event during colon carcinogenesis

Q42816270

Phosphorylation of the eukaryotic translation initiation factor eIF4E contributes to its transformation and mRNA transport activities

Q42822974

Clinical outcome in stage I to III breast carcinoma and eIF4E overexpression

Q48030230

p53-dependent translational control of senescence and transformation via 4E-BPs.

Q53305156

Detection of the proto-oncogene eIF4E in surgical margins may predict recurrence in head and neck cancer

Q59263687

Elevated expression of eIF4E and FGF-2 isoforms during vascularization of breast carcinomas

Q59263692

The proto-oncogene/translation factor eIF4E: A survey of its expression in breast carcinomas

Q59263746

Regulated phosphorylation and low abundance of HeLa cell initiation factor eIF-4F suggest a role in translational control. Heat shock effects on eIF-4F

Q69693940

Overexpression of the proto-oncogene/translation factor 4E in breast-carcinoma cell lines

Q71081176

Serine 209, not serine 53, is the major site of phosphorylation in initiation factor eIF-4E in serum-treated Chinese hamster ovary cells

Q72036803

Phosphorylation of eIF-4E on Ser 209 in response to mitogenic and inflammatory stimuli is faithfully detected by specific antibodies

Q73984086

Expression of eukaryotic translation initiation factors 4E and 2alpha is increased frequently in bronchioloalveolar but not in squamous cell carcinomas of the lung

Q74610149

[Treatment of non-small cell lung cancer in elderly patients]

Q80467430

The role of the 5' untranslated region of an mRNA in translation regulation during development

Q33601649

Expression of eIF4E during head and neck tumorigenesis: possible role in angiogenesis

Q33709452

mRNAs containing extensive secondary structure in their 5' non-coding region translate efficiently in cells overexpressing initiation factor eIF-4E

Q33938526

Translational control of malignancy: the mRNA cap-binding protein, eIF-4E, as a central regulator of tumor formation, growth, invasion and metastasis

Q33992131

Cell cycle checkpoint defects contribute to genomic instability in PTEN deficient cells independent of DNA DSB repair.

Q34017915

Mnk earmarks eIF4E for cancer therapy

Q34069446

Combined deficiency for MAP kinase-interacting kinase 1 and 2 (Mnk1 and Mnk2) delays tumor development

Q34069663

eIF4E phosphorylation promotes tumorigenesis and is associated with prostate cancer progression

Q34069836

Protein phosphatase 2A negatively regulates eukaryotic initiation factor 4E phosphorylation and eIF4F assembly through direct dephosphorylation of Mnk and eIF4E.

Q34177252

Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy

Q34306865

Phosphorylation of eukaryotic translation initiation factor 4E is critical for growth

Q34323752

Crystal structures of the Mnk2 kinase domain reveal an inhibitory conformation and a zinc binding site

Q34458528

PI3K and mTOR inhibitors: a new generation of targeted anticancer agents

Q34939865

Does phosphorylation of the cap-binding protein eIF4E play a role in translation initiation?

Q34992458

Translational control and metastatic progression: enhanced activity of the mRNA cap-binding protein eIF-4E selectively enhances translation of metastasis-related mRNAs

Q35125475

Mnk2 and Mnk1 are essential for constitutive and inducible phosphorylation of eukaryotic initiation factor 4E but not for cell growth or development

Q35663786

Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health

Q35679353

Protein kinase inhibitors: insights into drug design from structure.

Q35697409

eIF-4E expression and its role in malignancies and metastases.

Q35750118

eIF4E is a central node of an RNA regulon that governs cellular proliferation

Q36119000

Dissecting eIF4E action in tumorigenesis

Q36209711

Inhibition of mammalian target of rapamycin induces phosphatidylinositol 3-kinase-dependent and Mnk-mediated eukaryotic translation initiation factor 4E phosphorylation

Q36315668

Expression of antisense RNA against initiation factor eIF-4E mRNA in HeLa cells results in lengthened cell division times, diminished translation rates, and reduced levels of both eIF-4E and the p220 component of eIF-4F.

Q36741222

Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations

Q36742629

Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation

Q36971030

New modes of translational control in development, behavior, and disease

Q37033136

Tissue microarray analysis of eIF4E and its downstream effector proteins in human breast cancer

Q37074177

Cyclin-dependent kinase 9: a key transcriptional regulator and potential drug target in oncology, virology and cardiology.

Q37142722

eIF4E, the mRNA cap-binding protein: from basic discovery to translational research

Q37149933

The Mnks: MAP kinase-interacting kinases (MAP kinase signal-integrating kinases).

Q37175518

Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways.

Q37837732

Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy.

Q37865381

Discovery of cercosporamide, a known antifungal natural product, as a selective Pkc1 kinase inhibitor through high-throughput screening

Q39601355

Dual targeting of AKT and mammalian target of rapamycin: a potential therapeutic approach for malignant peripheral nerve sheath tumor

Q39856372

P275

Creative Commons Attribution 2.5 Generic

Q18810333

P433

issue

P407

language of work or name

English

Q1860

P921

main subject

transport protein

ribosomal proteins

peptide

enzyme

intracellular signaling peptides and proteins

Q67575047

P304

page(s)

118-131

P577

publication date

2012-02-01

P1433

published in

Oncotarget

Q1573155

P1476

title

Targeting Mnks for cancer therapy

P478

volume

Reverse relations

cites work (P2860)

Q36477529	4E-BP restrains eIF4E phosphorylation
Q38758276	AMP-activated Protein Kinase Up-regulates Mitogen-activated Protein (MAP) Kinase-interacting Serine/Threonine Kinase 1a-dependent Phosphorylation of Eukaryotic Translation Initiation Factor 4E.
Q38122226	Adaptation to chronic mTOR inhibition in cancer and in aging.
Q36945944	Adaptations to chronic rapamycin in mice.
Q27686983	Advances in targeting signal transduction pathways
Q38989374	Approved and Experimental Small-Molecule Oncology Kinase Inhibitor Drugs: A Mid-2016 Overview
Q35832986	Chorein addiction in VPS13A overexpressing rhabdomyosarcoma cells
Q39010703	Discovery of 5-(2-(phenylamino)pyrimidin-4-yl)thiazol-2(3H)-one derivatives as potent Mnk2 inhibitors: synthesis, SAR analysis and biological evaluation
Q37180382	Discovery of a BTK/MNK dual inhibitor for lymphoma and leukemia
Q38915711	Dissecting major signaling pathways in prostate cancer development and progression: Mechanisms and novel therapeutic targets
Q36117958	Distinct recruitment of human eIF4E isoforms to processing bodies and stress granules
Q38637354	Dual abrogation of MNK and mTOR: a novel therapeutic approach for the treatment of aggressive cancers
Q39038481	Dynamical insights of Mnk2 kinase activation by phosphorylation to facilitate inhibitor discovery
Q36556350	Ectopic NGAL expression can alter sensitivity of breast cancer cells to EGFR, Bcl-2, CaM-K inhibitors and the plant natural product berberine
Q37099708	Essential role for the Mnk pathway in the inhibitory effects of type I interferons on myeloproliferative neoplasm (MPN) precursors
Q41257613	Expression of eukaryotic initiation factor 4E and 4E binding protein 1 in colorectal carcinogenesis
Q37660329	First MNKs degrading agents block phosphorylation of eIF4E, induce apoptosis, inhibit cell growth, migration and invasion in triple negative and Her2-overexpressing breast cancer cell lines
Q92166398	First-in-Human, Healthy Volunteers Integrated Protocol of ETC-206, an Oral Mnk 1/2 Kinase Inhibitor Oncology Drug
Q46713797	Impact of genetic variations in the MAPK signaling pathway on outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI and bevacizumab: data from FIRE-3 and TRIBE trials
Q42513156	Inhibiting ERK/Mnk/eIF4E broadly sensitizes ovarian cancer response to chemotherapy.
Q37709399	Inhibiting the MNK-eIF4E-β-catenin axis increases the responsiveness of aggressive breast cancer cells to chemotherapy
Q37636705	Inhibition of Mnk enhances apoptotic activity of cytarabine in acute myeloid leukemia cells
Q36814636	Inhibition of Mnk kinase activity by cercosporamide and suppressive effects on acute myeloid leukemia precursors
Q38736366	Inhibition of Mnk-eIF4E pathway sensitizes the efficacy to chemotherapy in anaplastic thyroid cancer
Q39778668	Insights into the Importance of DFD-Motif and Insertion I1 in Stabilizing the DFD-Out Conformation of Mnk2 Kinase
Q36368266	Interleukin-10 inhibits lipopolysaccharide-induced tumor necrosis factor-α translation through a SHIP1-dependent pathway
Q57292823	MNK1 inhibitor CGP57380 overcomes mTOR inhibitor-induced activation of eIF4E: the mechanism of synergic killing of human T-ALL cells
Q47649072	MNK1/2 inhibition limits oncogenicity and metastasis of KIT-mutant melanoma
Q34545783	MNKs act as a regulatory switch for eIF4E1 and eIF4E3 driven mRNA translation in DLBCL.
Q47753117	Major splice variants and multiple polyadenylation site utilization in mRNAs encoding human translation initiation factors eIF4E1 and eIF4E3 regulate the translational regulators?
Q34450669	Mechanical stimulation induces mTOR signaling via an ERK-independent mechanism: implications for a direct activation of mTOR by phosphatidic acid
Q36635382	MicroRNA-7 control of β-cell replication
Q26865459	Mnk kinase pathway: Cellular functions and biological outcomes
Q42427245	New insights into malignant cell survival mechanisms in medulloblastoma
Q89870181	Nicotinamide-Ponatinib Analogues as Potent Anti-CML and Anti-AML Compounds
Q36140862	Notch signaling sustains the expression of Mcl-1 and the activity of eIF4E to promote cell survival in CLL.
Q55068343	Novel C-4 heteroaryl 13-cis-retinamide Mnk/AR degrading agents inhibit cell proliferation and migration and induce apoptosis in human breast and prostate cancer cells and suppress growth of MDA-MB-231 human breast and CWR22Rv1 human prostate tumor x
Q39114297	Oncogenic activation of MEK/ERK primes melanoma cells for adaptation to endoplasmic reticulum stress.
Q94599757	Osimertinib successfully combats EGFR-negative glioblastoma cells by inhibiting the MAPK pathway
Q41942808	Pharmacological targeting of eIF4E in primary CLL lymphocytes
Q35097767	Phosphorylated Mnk1 and eIF4E are associated with lymph node metastasis and poor prognosis of nasopharyngeal carcinoma
Q33620730	Protein expression of eIF4E and integrin αvβ6 in colon cancer can predict clinical significance, reveal their correlation and imply possible mechanism of interaction
Q42019006	Pyrrolopyrimidine Analogues as MKNK Inhibitors
Q38959287	Regulatory effects of a Mnk2-eIF4E feedback loop during mTORC1 targeting of human medulloblastoma cells
Q39139050	Repression of microRNA-768-3p by MEK/ERK signalling contributes to enhanced mRNA translation in human melanoma
Q34392470	Selective anti-cancer agents as anti-aging drugs
Q54118148	Signaling pathways involved in the regulation of mRNA translation.
Q26777735	Signalling to eIF4E in cancer
Q38918208	Simultaneous targeting of androgen receptor (AR) and MAPK-interacting kinases (MNKs) by novel retinamides inhibits growth of human prostate cancer cell lines
Q55711374	Small Molecules Targeting the Inactive Form of the Mnk1/2 Kinases.
Q35567160	Stat1 stimulates cap-independent mRNA translation to inhibit cell proliferation and promote survival in response to antitumor drugs
Q38871487	Sulfoximine substituted quinazolines for pharmaceutical compositions US 20150005278 (A1): a patent evaluation
Q52340912	Synergistic effects of inhibiting the MNK-eIF4E and PI3K/AKT/ mTOR pathways on cell migration in MDA-MB-231 cells.
Q38847261	TRM6/61 connects PKCα with translational control through tRNAi(Met) stabilization: impact on tumorigenesis.
Q92524896	Targeting CDK9 for treatment of colorectal cancer
Q34365839	Targeting RNA transcription and translation in ovarian cancer cells with pharmacological inhibitor CDKI-73.
Q39172901	Targeting of protein translation as a new treatment paradigm for prostate cancer
Q38699320	Targeting translation: eIF4E as an emerging anticancer drug target
Q38920048	The MAP kinase-interacting kinases regulate cell migration, vimentin expression and eIF4E/CYFIP1 binding
Q52684450	The unfolded protein response: a novel therapeutic target for poor prognostic BRAF mutant colorectal cancer.
Q36473355	Therapeutic interventions to disrupt the protein synthetic machinery in melanoma
Q38791406	Unveiling new chemical scaffolds as Mnk inhibitors.
Q36294841	Up-regulation of translation eukaryotic initiation factor 4E in nucleophosmin 1 haploinsufficient cells results in changes in CCAAT enhancer-binding protein α activity: implications in myelodysplastic syndrome and acute myeloid leukemia.
Q54988438	miR-134 increases the antitumor effects of cytarabine by targeting Mnks in acute myeloid leukemia cells.
Q64107786	miR-483-5p Targets MKNK1 to Suppress Wilms' Tumor Cell Proliferation and Apoptosis In Vitro and In Vivo
Q37321076	peIF4E as an independent prognostic factor and a potential therapeutic target in diffuse infiltrating astrocytomas.

P356	DOI	10.18632/ONCOTARGET.453
P932	PMC publication ID	3326643
P698	PubMed publication ID	22392765